Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals

Article Abstract:

People who have albumin in their urine may have a higher than normal risk of heart attack, stroke, or death from cardiovascular disease. Albumin is a protein in the body that is not normally present in urine. Its presence may indicate a malfunction of blood vessels.

Author: Gerstein, Hertzel C., Yusuf, Salim, Mann, Johannes F. E., Yi, Qilong, Zinman, Bernard, Dinneen, Sean F., Hoogwerf, Byron, Halle, Jean Pierre, Young, James, Rashkow, Andrew, Joyce, Carol, Nawaz, Shah
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Cardiovascular diseases, Patient outcomes, Mortality, Risk factors, Stroke (Disease), Stroke, Albuminuria

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Ramipril and the Development of Diabetes

Article Abstract:

The ACE inhibitor ramipril can lower the risk of type 2 diabetes in people who have a high risk of developing adult-onset diabetes. In a study of 5,720 patients at high risk of type 2 diabetes, those who took ramipril were about 40% less likely to develop the disease.

Author: Yusuf, Salim, Zinman, Bernard, Hoogwerf, Byron, Gerstein, Hertzel, Pogue, Janice, Bosch, Jackie, Wolffenbuttel, Bruce H. R.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Prevention, Ramipril, ACE inhibitors, Angiotensin converting enzyme inhibitors, Type 2 diabetes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction

Article Abstract:

It is too early to tell if coronary angioplasty is superior to thrombolytic drugs in the treatment of patients with a heart attack. These two techniques are used to open clogged arteries and dissolve the blood clots that cause most heart attacks. A 1997 meta-analysis reviewed 10 clinical trials and found that 30-day mortality rates were slightly lower in patients who received angioplasty. However, a longer follow-up in other studies shows that the benefit often disappears within six months. In addition, the 10 studies altogether only evaluated 2,606 patients, but about 12,700 would be needed to see a significant difference.

Author: Yusuf, Salim, Pogue, Janice
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
Care and treatment, Editorial, Usage, Evaluation, Transluminal angioplasty, Balloon angioplasty, Thrombolytic therapy, Meta-analysis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Heart attack
Similar abstracts:
  • Abstracts: The Accuracy of Patient History, Wheezing, and Laryngeal Measurements in Diagnosing Obstructive Airway Disease
  • Abstracts: Anthropometry and methods of body composition measurement for research and field application in the elderly. Multi-component body composition models: recent advances and future directions
  • Abstracts: Endocannabinoids acting at vascular CB (sub)1 receptors mediate the vasodilated state in advanced liver cirrhosis
  • Abstracts: Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range
  • Abstracts: Development and progression of renal disease in Pima indians with non-insulin-dependent diabetes mellitus. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.